Ann: Half Yearly Report and Accounts, page-11

With cash to run for 5 quarters you think there will be not one cent from any projects ?

China ?
The Company entered into a distribution agreement with China based Shanghai GeneoDx Biotechnology Co. Ltd (“GeneoDx” (ASX Release 13 December 2018) which is an affiliated company of China National Pharmaceutical Group (SINOPHARM). This agreement provides immediate access to an extremely large and rapidly growing PoC market and provides, through GeneoDx, access to a vibrant and diverse PoC manufacturing sector eager to embrace new technology and incorporate product enhancing components,

Ellume’s success during the half year in securing a significant partnership with global healthcare group GlaxoSmithKline (“GSK” focused on improving respiratory care. The integration of the Anteo technology into PoC systems, similar to those being developed by partners such as Ellume, demonstrates the importance of the supporting role Anteo is playing by supplying valuable components that then enable superior performance of diagnostic systems. Anteo has enjoyed a positive and collaborative R&D partnership with Ellume since 2016.

Anteo Battery tec has industry disruptive results at hand ? Battery partners will move quicker than you think for 1st mover industry leading drop in composite applications.

POC ? Particle Conjugation Kits are for sale now ,development of “quantitative” (providing a numeric, more accurate result vs the traditional positive (+) or negative (-) result) PoC assays for critical applications such as Cardiac (Troponin) or Infectious Disease testing (Flu or HIV).
Anteo reinvigorated its relationship with IMRA to complete the development of a “ready-to-use” Gold Conjugation Kit. The Company has been progressing this development process and is pleased to report that all technical performance elements have been satisfactorily completed.

Anteo was a collaborating partner in the Defence Materials Technology Centre (“DMTC”/ Medical Countermeasures (“MCM” project team which won a National Innovation Award at the international Land Forces 2018 Exposition in Adelaide. The project was for development of a fielddeployable, handheld diagnostic device which will enable medical professionals to rapidly identify and treat life-threatening diseases through a diagnostic system that can detect and differentiate between multiple infectious disease agents within a single test cartridge at the point of care. Lumos Diagnostics.

All these Irons in the fire with only a $20 million market cap ? good luck finding a better blue sky Bio investment.